Nasus Pharma Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NSRX research report →
Range $22 – $22
Price Chart
About the company
Nasus Pharma Ltd. , a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
- CEO
- Dan Teleman
- IPO
- 2025
- Employees
- 7
- HQ
- Tel Aviv, TA, IL
Get TickerSpark's AI analysis on NSRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $27.04M
- P/E
- -18.47
- PEG
- -0.18
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -17.76
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.00%
- ROIC
- 0.00%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,078,000
- Net Income
- $-1,532,000-45.8%
- EPS
- $-0.17-41.7%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $9.99
- 52W Low
- $1.98
- 50D MA
- $3.09
- 200D MA
- $4.98
- Beta
- 5.02
- RSI (14)
- 51
- Avg Volume
- 43.74K
No earnings-call transcripts are available for NSRX yet.
- Free Float
- 33.1%
- Shares Outstanding
- 8.61M
- Float Shares
- 2.85M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 17, 26 | Teleman Dan Benjamin | buy | 6,550 |
| Apr 22, 26 | Teleman Dan Benjamin | buy | 2,900 |
| Mar 31, 26 | Teleman Dan Benjamin | buy | 15,000 |
| Nov 20, 26 | Rubin Eyal | other | 40,549 |
| Mar 11, 26 | Silberman David | other | 10,000 |
| Mar 18, 26 | Teleman Dan Benjamin | other | 0 |
| Jan 7, 26 | Teleman Dan Benjamin | other | 318,856 |
| Mar 11, 26 | Shacham Sharon | other | 10,000 |
| Mar 18, 26 | Gilboa Udi | other | 0 |
| Mar 18, 26 | Gilboa Udi | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NSRX coverage
Recent articles, reports, and earnings notes.
No research on NSRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NSRX report →Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum
globenewswire.com · Jun 22
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
globenewswire.com · Jun 9
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
globenewswire.com · Jun 1
Nasus Pharma to Participate in Upcoming Investor Conferences
globenewswire.com · May 1
Nasus Pharma to Participate in Upcoming Investor Conferences
globenewswire.com · May 1
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
globenewswire.com · Mar 25
BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript
globenewswire.com · Mar 19
What's Going On With Nasus Pharma Stock On Wednesday
benzinga.com · Mar 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Bullish or bearish?
Where do you stand on NSRX?